SCHEMBL4150094

SCHEMBL4150094

O=C(N[C@H]1CCCN(c2ccc(-c3ccccc3)cc2)C1)N1C2CCC1CC(O)C2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.47
NPSR1 Q6W5P4 1/20 0.44
MCHR1 Q99705 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
GAA P10253 1/20 0.40
CHRM1 P11229 1/20 0.40
PPARA Q07869 2/20 0.39
PPARD Q03181 1/20 0.39
USP2 O75604 1/20 0.39
MAPK1 P28482 1/20 0.39
CASR P41180 1/20 0.39
NAMPT P43490 1/20 0.39
DRD2 P14416 1/20 0.39
DRD4 P21917 1/20 0.39
USP30 Q70CQ3 2/20 0.39
ALDH1A1 P00352 2/20 0.38
FFAR4 Q5NUL3 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
CTSL P07711 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4011753 1.00 CNR1 (0.47) CNR1NPSR1MCHR1SMN1; SMN2GAA
SCHEMBL5950313 0.93 CNR1 (0.53) CNR1NPSR1SMN1; SMN2GAACHRM1
SCHEMBL5950786 0.87 CNR1 (0.41) CNR1NPSR1SMN1; SMN2GAACHRM1
SCHEMBL4004043 0.87 CNR1 (0.41) CNR1NPSR1SMN1; SMN2GAACHRM1
SCHEMBL4003357 0.87 POLB (0.49) CNR1NPSR1PPARAPPARDMAPK1
SCHEMBL4003351 0.87 POLB (0.49) CNR1NPSR1PPARAPPARDMAPK1
SCHEMBL4138489 0.86 CNR1 (0.51) CNR1NPSR1MCHR1GAAUSP2
SCHEMBL4138485 0.86 CNR1 (0.51) CNR1NPSR1MCHR1GAAUSP2
SCHEMBL4003634 0.84 NOTUM (0.46) CNR1NPSR1MCHR1MEN1KMT2A
SCHEMBL5950811 0.84 USP14 (0.40) CNR1NPSR1USP30CTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060122197-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-06-08 US claimed
EP-1778229-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2009-06-17 EP disclosed
EP-1778229-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-05-02 EP disclosed
US-20060122197-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-06-08 US disclosed
WO-2006020598-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122197-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 CNR1 516/4885NPSR1 615/4885MCHR1 706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.